Featuring an interview with Dr John V Heymach, including the following topics:
- Differentiating factors among various HER2 alterations in non-small cell lung cancer (NSCLC) (0:00)
- Activity of targeted agents across HER2 alterations in NSCLC (4:06)
- Available data with zongertinib and sevabertinib for HER2-mutant NSCLC (20:39)
- Case: A man in his late 40s with HER2-mutant NSCLC receives multiple lines of therapy, including trastuzumab deruxtecan (T-DXd) and zongertinib (29:23)
- Case: A woman in her mid 50s with HER2-mutant NSCLC receives zongertinib with durable response (34:23)
- Case: A woman in her late 50s with HER2-mutant NSCLC receives multiple lines of therapy, including sevabertinib and T-DXd (39:53)
- Investigational approaches in HER2-mutant NSCLC (46:31)